Fund of the Week: ClearBridge Aggressive Growth A Fund (SHRAX)

Welcome to MutualFunds.com

Please help us personalize your experience and select the one that best describes you.

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.
Not interested

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission

We hope you enjoy your experience

Channels

Fixed Income Channel

Fixed income news, reports, video and more.

Municipal Bonds Channel

Municipal bonds news, reports, video and more.

Practice Management Channel

Practice management news, reports, video and more.

Portfolio Management Channel

Portfolio management news, reports, video and more.

Retirement Channel

Retirement news, reports, video and more.

Strategists Channel

Learn from industry thought leaders and expert market participants.

Charles Schwab IMPACT 2019 Channel

Find the latest content and information here about the 2019 Charles Schwab Impact Conference.

Screener
Funds
Categories

18 Most Popular Mutual Fund Categories

Canada Equity Funds Global Equity Funds Micro-Cap Equity Funds Precious Metals Equity Funds Water Equity Funds
Consumer Staples Funds US Funds China Funds Israel Funds Retirement Income Funds
Bear Market Strategy Funds Market Neutral Funds Alternative Funds Commodity Funds
Currency Funds Mortgage-Backed Securities Funds High Yield Municipal Bond Funds Money Market Funds

View All Categories

Fund Companies

15 Most Popular Fund Companies

Vanguard Fidelity Investments American Funds T. Rowe Price
JPMorgan BlackRock Dimensional Fund Advisors Franklin Templeton
PIMCO Goldman Sachs Federated MFS
Charles Schwab John Hancock Invesco

View All Fund Companies

15 Most Popular Fund Company Quick Screens

Vanguard Index Funds Vanguard Retirement Funds Vanguard Money Market Funds Fidelity Index Funds
Fidelity Money Market Funds Fidelity Blue Chip Growth Equity Funds American Balanced Funds T. Rowe Price Blue Chip Growth Equity Funds
Blackrock Global Allocation Funds Franklin Income Funds PIMCO Income Funds Charles Schwab Index Funds
Charles Schwab Money Market Funds Invesco Real Estate Funds Matthews Asia International Funds

View All Fund Company Quick Screens

Articles

Articles

Mutual Fund Education Index Fund Center Domestic Stock Funds International and Global Stock Funds Target-Date Funds
Fixed-Income Funds Asset Allocation Specialized Funds Enhanced Index Funds Actively Managed Funds
No-Load Funds Bond Funds Equity Funds Hybrid Funds Resources For Mutual Fund Investors
Q&As and Interviews Lighter Side: Quizzes and More Taxation Expert Analysis and Commentary News
Advisors

Advisor Access

Receive email updates about fund flows, news, upcoming CE accredited webcasts from industry thought leaders and more.

Practice Management

Content focused on helping financial advisors build successful client relationships and grow their business.

Portfolio Management

Content geared towards helping financial advisors build better client portfolios.

Expert Opinion

Get insights on the industry trends and investment news from leading fund managers and experts.

Advisor Access
You have successfully subscribed to Advisor Access. Thank you!
Help us personalize your experience.
Which type of investor describes you best?
Help us personalize your experience.
What is your AUM?
Knowing your investable assets will help us build and prioritize features that will suit your investment needs.

Congratulations on personalizing your experience.

Email is verified. Thank you!

Fund of the Week: ClearBridge Aggressive Growth A Fund (SHRAX)

Financial Research
“Patient management seeks capital appreciation from a high-conviction portfolio or companies with new or innovative technologies, products and services.” -ClearBridge Investments
The Aggressive Growth A Fund from ClearBridge Investments has an opportunistic mandate allowing for a more speculative large cap stock selection. With $15.4 billion in net assets and only 71 holdings, the fund has been chosen this week as it provides investors access to the defensive but high growth healthcare sector. Traditionally in the event of a market correction, this segment of the market continues to perform well. This is supported by the performance of L&G Global Health & Pharmaceutical Index, which returned 2.7% in 2007, 8.4% in 2008 and 8.4% in 2009 as well as Schroders Global Healthcare portfolio which outperformed the market considerably during this period. Surprisingly this fund has a low turnover rate of 5%, which puts it into the 1st Quintile of Mutual funds using that metric.

Type of Fund

This fund is an open ended retail mutual fund, with a $1000 minimum investment requirement for standard accounts and $250 for IRA accounts. The expense ratio is 1.15%.

Manager Profile

Richard Freeman has 38 years of experience and co-manages the fund with Evan Bauman. Starting his career at Shearson American Express, he holds an MBA in Finance from New York University. Evan Bauman holds a BS in Mathematics from Duke University and has 18 years investment experience.

Performance

Return Ranking - Calendar
Period SHRAX Return Category Return Low Category Return High Rank in Category (%) Quintile
2014 12.30% -0.70% 12.30% 11.11% 1
2013 43.40% 23.90% 43.40% 11.11% 1
2012 15.10% 10.80% 19.60% 77.78% 4
2011 -0.90% -12.10% 12.50% 66.67% 3
2010 23.90% 11.40% 23.90% 11.11% 1
SHRAX has a year to date performance of 3.0%, which puts the fund in the 4th quintile for its category. Relatively conservative this year, the fund in 2014 posted a 12.3% return and in 2013 a 43.4% return. It was consistently ranked in the 1st quantile for both years and has only had one negative year in the last five.

Dividend Analysis

The fund is not an income vehicle.

Asset Allocation Weightings

Unlike the last fund we digested, SHRAX holds a concentrated equities portfolio with very little asset diversification. Current weightings are:
  • 88.79% Stocks
  • 0.00% Bonds
  • 10.17% Cash
  • 0.04% Other
  • 0.00% Preferred Stocks
  • 0.00% Convertible Bonds

Portfolio Sector Weightings

Portfolio Sector Weightings
An interesting combination of defensive and cyclical sectors, with a significant percentage of the total portfolio invested in the high growth sectors of healthcare and technology.

Top 10 Holdings

Biogen and United Health Group are the top two weighted holdings, and account for 16.03% of the total equities portfolio. Amgen, which accounts for 5.19% of the portfolio recently had their cholesterol lowering “Rapatha” approved by the FDA. Its stock was upgraded to strong buy by crowdsourced ratings platform Vetr. Another stock that has become a recent darling with analysts is that of Anardarko Petroleum. The lone energy company within the top 10 holdings, its stock was upgraded by Jeffries on the 7th with a new price target of $88.00.

Concerns

Primary concern is the reduced number of holdings in comparison to its peers. SHRAX sits in the 4th quintile for this category. As a growth mandated fund the stock selection, although large cap, could be higher risk and translate into higher volatility.

Bottom Line

An interesting fund that offers a slightly different approach to its peers, its positive features include low turnover rate, defensive equity holdings and the ability to invest in high growth large cap opportunities. Caution should be taken though when investing, as the fund has a high stock concentration with the top 3 sectors accounting for 63.36% of the total equity allocation. To dig a little deeper into SHRAX, click here.

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Popular Articles

Download our free report

Find out why $30 trillon is invested in mutual funds.

Why 30 trillion is invested in mutual funds book

Why 30 trillion is invested in mutual funds book

Download our free report

Find out why $30 trillon is invested in mutual funds.

Why 30 trillion is invested in mutual funds book

Download our free report

Find out why $30 trillon is invested in mutual funds.

Read Next

Financial Research

Fund of the Week: ClearBridge Aggressive Growth A Fund (SHRAX)

“Patient management seeks capital appreciation from a high-conviction portfolio or companies with new or innovative technologies, products and services.” -ClearBridge Investments
The Aggressive Growth A Fund from ClearBridge Investments has an opportunistic mandate allowing for a more speculative large cap stock selection. With $15.4 billion in net assets and only 71 holdings, the fund has been chosen this week as it provides investors access to the defensive but high growth healthcare sector. Traditionally in the event of a market correction, this segment of the market continues to perform well. This is supported by the performance of L&G Global Health & Pharmaceutical Index, which returned 2.7% in 2007, 8.4% in 2008 and 8.4% in 2009 as well as Schroders Global Healthcare portfolio which outperformed the market considerably during this period. Surprisingly this fund has a low turnover rate of 5%, which puts it into the 1st Quintile of Mutual funds using that metric.

Type of Fund

This fund is an open ended retail mutual fund, with a $1000 minimum investment requirement for standard accounts and $250 for IRA accounts. The expense ratio is 1.15%.

Manager Profile

Richard Freeman has 38 years of experience and co-manages the fund with Evan Bauman. Starting his career at Shearson American Express, he holds an MBA in Finance from New York University. Evan Bauman holds a BS in Mathematics from Duke University and has 18 years investment experience.

Performance

Return Ranking - Calendar
Period SHRAX Return Category Return Low Category Return High Rank in Category (%) Quintile
2014 12.30% -0.70% 12.30% 11.11% 1
2013 43.40% 23.90% 43.40% 11.11% 1
2012 15.10% 10.80% 19.60% 77.78% 4
2011 -0.90% -12.10% 12.50% 66.67% 3
2010 23.90% 11.40% 23.90% 11.11% 1
SHRAX has a year to date performance of 3.0%, which puts the fund in the 4th quintile for its category. Relatively conservative this year, the fund in 2014 posted a 12.3% return and in 2013 a 43.4% return. It was consistently ranked in the 1st quantile for both years and has only had one negative year in the last five.

Dividend Analysis

The fund is not an income vehicle.

Asset Allocation Weightings

Unlike the last fund we digested, SHRAX holds a concentrated equities portfolio with very little asset diversification. Current weightings are:
  • 88.79% Stocks
  • 0.00% Bonds
  • 10.17% Cash
  • 0.04% Other
  • 0.00% Preferred Stocks
  • 0.00% Convertible Bonds

Portfolio Sector Weightings

Portfolio Sector Weightings
An interesting combination of defensive and cyclical sectors, with a significant percentage of the total portfolio invested in the high growth sectors of healthcare and technology.

Top 10 Holdings

Biogen and United Health Group are the top two weighted holdings, and account for 16.03% of the total equities portfolio. Amgen, which accounts for 5.19% of the portfolio recently had their cholesterol lowering “Rapatha” approved by the FDA. Its stock was upgraded to strong buy by crowdsourced ratings platform Vetr. Another stock that has become a recent darling with analysts is that of Anardarko Petroleum. The lone energy company within the top 10 holdings, its stock was upgraded by Jeffries on the 7th with a new price target of $88.00.

Concerns

Primary concern is the reduced number of holdings in comparison to its peers. SHRAX sits in the 4th quintile for this category. As a growth mandated fund the stock selection, although large cap, could be higher risk and translate into higher volatility.

Bottom Line

An interesting fund that offers a slightly different approach to its peers, its positive features include low turnover rate, defensive equity holdings and the ability to invest in high growth large cap opportunities. Caution should be taken though when investing, as the fund has a high stock concentration with the top 3 sectors accounting for 63.36% of the total equity allocation. To dig a little deeper into SHRAX, click here.

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Popular Articles

Download our free report

Find out why $30 trillon is invested in mutual funds.

Why 30 trillion is invested in mutual funds book

Why 30 trillion is invested in mutual funds book

Download our free report

Find out why $30 trillon is invested in mutual funds.

Why 30 trillion is invested in mutual funds book

Download our free report

Find out why $30 trillon is invested in mutual funds.

Read Next

Advertisement

×

Wait! Do you know all the important aspects of mutual funds?

×

Free Advisor Access newsletter emailed to you.

Receive free and exclusive email updates for financial advisors about best performers, news, CE accredited webcasts and more.

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Disclaimer: By registering, you agree to share your data with MutualFunds.com and opt-in to receiving occasional communications about projects and events. The contents of this form are subject to the MutualFunds.com Privacy Policy. You can unsubscribe at any time.

X